As the Detroit Tigers navigate a 20-31 start to the 2026 season, star pitcher Tarik Skubal’s trade value has become a focal point of MLB’s winter market, with rival executives offering stark assessments of what the Tigers might command for the left-hander. Skubal, who underwent elbow surgery 15 days prior, has shown progress in his recovery, but his status as a “two-month rental” with injury risk complicates potential deals.
Executives Paint a Complex Picture of Skubal’s Trade Value
Rival executives provided divergent but revealing insights into what the Tigers might receive for Skubal, a 2025 Cy Young finalist who remains under contract through 2026. One executive emphasized the rarity of Skubal’s situation: “I don’t think anyone can answer that. I don’t think we have ever seen a pitcher this good coming off such a bizarre injury.” The executive speculated that a trade could net “one top-100 prospect plus a top-15 and one more throw in,” though he added, “The Padres will” — suggesting San Diego’s willingness to meet the Tigers’ asking price.
Another executive, focusing on the urgency of the August 3 trade deadline, framed Skubal as a high-stakes asset: “You get two starts in that five-game series. Friedman gets him, that’s my prediction.” This reference to Tampa Bay Rays president Andrew Friedman highlights the premium teams like the Rays, who prioritize playoff odds, might place on Skubal. However, the executive cautioned that most teams would approach the trade as “asset value” rather than a long-term investment, potentially limiting returns to “a couple of top 10 prospects for a couple months of him.
The third executive underscored the financial hurdles: “Skubal is tough though as a two month rental with injury risk because it’s tough for a team to just come up with the close to $12-14 million he will be owed after a trade that isn’t budgeted for.” This comment reflects the logistical challenge of absorbing Skubal’s salary, which the Tigers could mitigate by “paying down the salary” to attract better offers.
For more on this story, see Tarik Skubal Trade Rumors Grow as Tigers Ace Nears Return From Surgery.
Skubal’s Recovery Progress and Uncertainties
Skubal’s physical progress since his elbow surgery has been a critical factor in trade discussions. Two weeks post-procedure, he completed a multi-inning bullpen session designed to simulate game conditions, achieving “high-end velocity for his bullpen sessions” but falling short of “game velocity.” “It comes out a little bit slower than a game,” he noted, “but it’s relatively close.” Manager A.J. Hinch praised Skubal’s determination, adding, “He came into my office right away and was excited.
Despite the encouraging signs, Skubal acknowledged the unprecedented nature of his recovery: “I don’t know in the history of the game if there has been a surgery 15 days ago and throwing a one-inning hypothetical start.” He emphasized the need for caution, stating, “I get it, I want to be back as fast as possible, but I also need to be back and be healthy.” His next steps include a “more normal, between-starts bullpen” in Baltimore, followed by another session early next week.
Historical Context and Trade Precedents
The Tigers’ dilemma mirrors past decisions by teams facing similar crossroads. In 1997, the Montreal Expos traded Pedro Martínez to the Red Sox despite his Cy Young pedigree, a move that ultimately proved transformative for both teams. Martínez’s case highlights how a pitcher’s trade value can hinge on a team’s long-term strategy and financial flexibility. For the Tigers, the decision to hold or sell Skubal will depend on whether they view him as a cornerstone or a short-term asset. <a href="https://www.nytimes.
Analysts note that Skubal’s trade value could be influenced by the Tigers’ playoff aspirations. While the team is not in full rebuild mode, their 20-31 record suggests they may prioritize long-term gains over short-term wins. However, Skubal’s injury history and the limited time he could contribute before the 2026 season’s end complicate this calculus. “It’s so difficult to tell,” one executive admitted, “but I think it would start at one top-50 and another top-100 prospect.
What’s Next for Skubal and the Tigers?
The coming weeks will be pivotal for Skubal’s recovery and the Tigers’ trade strategy. If he continues to progress, teams with playoff ambitions may be more inclined to take a chance on him, though the financial and medical risks remain. Conversely, if his rehab stalls, the Tigers could face pressure to sell low. Skubal himself has signaled a balance between urgency and caution: “I want to be back as fast as I can, too,” he said, “but I also need to be back and be healthy.
For now, the Tigers are walking a tightrope between competing priorities. As one executive put it, “It’s a matter of how much you’re willing to gamble on a pitcher coming off a bizarre injury.” With the trade deadline looming, the decisions made in the next 30 days could define the Tigers’ trajectory for years to come.
